Saltar al contenido
Merck

Calreticulin mutations and long-term survival in essential thrombocythemia.

Leukemia (2014-05-06)
A Tefferi, E A Wassie, T L Lasho, C Finke, A A Belachew, R P Ketterling, C A Hanson, A Pardanani, N Gangat, A P Wolanskyj
RESUMEN

The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining 12% were 'triple-negative'. We confirmed the association of mutant CALR (vs JAK2V617F) with younger age (P=0.002), male sex (P=0.01), higher platelet count (0.0004), lower hemoglobin (P<0.0001), lower leukocyte count (0.02) and lower incidence of recurrent thrombosis (0.04). Triple-negative patients were also younger than their JAK2-mutated counterparts (P=0.003) and displayed lower hemoglobin (P=0.003), lower leukocyte count (<0.0001) and lower thrombotic events (P=0.02). Median follow-up time was 12.7 years and 47% of the patients were followed until death. Survival was the longest for triple-negative and shortest for MPL-mutated patients. Median survival was 19 years for JAK2 and 20 years for CALR-mutated cases (P=0.32); the corresponding figures for patients of age ⩽65 years were 26 and 32 years (P=0.56). The two mutational categories were also similar for leukemic (P=0.28) and fibrotic (P=0.28) progression rates. The current study is uniquely characterized by its very long follow-up period and provides accurate estimates of long-term survival in ET and complements current information on mutation-specific phenotype and prognosis.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Hydroxyurea, 98%, powder
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Hydroxycarbamide, European Pharmacopoeia (EP) Reference Standard
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad